Jaguar LAA, a newly formed medtech, has acquired assets that are part of Johnson & Johnson’s Afib device Laminar program for an undisclosed price.
The Laminar device focuses on a catheter-based left atrial appendage (LAA) closure program originally developed by Laminar and snapped up by J&J in 2023 in a deal valued at $400 million.
The device uses a catheter-based approach and rotational motion to close and eliminate the LAA, all the while leaving minimal device exposure within the left atrium to help prevent strokes in patients, the company said.
Financial details of the deal weren’t disclosed.
The sale brings together both assets and members of the team that helped develop it under the umbrella of an independent company.
“We believe the Laminar technology offers a differentiated approach to LAA closure, particularly through its ability to leave minimal device exposure within the left atrium,” Jason Rogers, Jaguar’s chief medical officer, said in a statement. “We are excited to continue the work behind the program and explore its potential to provide an important new treatment option for patients with atrial fibrillation.”
The new company, not to be confused with Jaguar Gene Therapy, was formed with members of the Laminar management team, Santé Ventures and other investors.
Earlier this year, Austin, Texas-based Santé hauled in $330 million in its fifth and largest funding round, which it said it would use to invest in new biotechnology, med tech and digitally driven healthcare companies.